TITLE

EUROPEAN COMMISSION APPROVES SHORTENED HEPATITIS TREATMENT

PUB. DATE
August 2008
SOURCE
Worldwide Biotech;Aug2008, Vol. 20 Issue 8, p7
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article reports on the decision by the European Commission in 2008 to approve a shortened, 16-week course of treatment with Pegasys plus Copegus (ribavirin) for certain hepatitis C patients. It is noted that the shorter treatment duration will provide patients with the full benefits of therapy while reducing unnecessary drug exposure. Professor Stefan Zeuzem, Chief of the Department of Medicine I at the Johann-Wolfgang Goethe University Hospital in Frankfurt, Germany, explained the benefits of the approval.
ACCESSION #
33322425

 

Related Articles

  • Efficacy of re-treatment with pegylated interferon plus ribavirin combination therapy for patients with chronic hepatitis C in Japan. Oze, Tsugiko; Hiramatsu, Naoki; Yakushijin, Takayuki; Mochizuki, Kiyoshi; Oshita, Masahide; Hagiwara, Hideki; Mita, Eiji; Ito, Toshifumi; Inui, Yoshiaki; Fukui, Hiroyuki; Hijioka, Taizo; Katayama, Kazuhiro; Tamura, Shinji; Yoshihara, Harumasa; Inoue, Atsuo; Imai, Yasuharu; Hayashi, Eijiro; Kato, Michio; Hosui, Atsushi; Miyagi, Takuya // Journal of Gastroenterology;Aug2011, Vol. 46 Issue 8, p1031 

    Background: It is still not known which patients with chronic hepatitis C who failed to respond to previous pegylated interferon (Peg-IFN) plus ribavirin therapy can benefit from re-treatment. Methods: Seventy-four patients (HCV genotype 1, n = 56, genotype 2, n = 18) were re-treated with...

  • Efficacy of pegylated interferon plus ribavirin combination therapy for hepatitis C patients with normal ALT levels: a matched case-control study. Hiramatsu, Naoki; Inoue, Yuko; Oze, Tsugiko; Kurashige, Nao; Yakushijin, Takayuki; Mochizuki, Kiyoshi; Miyagi, Takuya; Tatsumi, Tomohide; Kiso, Shinichi; Kanto, Tatsuya; Kasahara, Akinori; Takehara, Tetsuo; Oshita, Masahide; Mita, Eiji; Hagiwara, Hideki; Inui, Yoshiaki; Katayama, Kazuhiro; Tamura, Shinji; Yoshihara, Harumasa; Imai, Yasuharu // Journal of Gastroenterology;Nov2011, Vol. 46 Issue 11, p1335 

    Background: The antiviral effect of pegylated interferon (Peg-IFN) plus ribavirin combination therapy in chronic hepatitis C (CHC) patients with normal alanine aminotransferase (ALT) levels (N-ALT) has been reported to be equivalent to that for patients with elevated ALT levels (E-ALT). However,...

  • Excitement grows for potential revolution in hepatitis C virus treatment. Opar, Alisa // Nature Reviews Drug Discovery;Jul2010, Vol. 9 Issue 7, p501 

    The article offers an update on the clinical phase trials of telaprevir from Vertex Pharmaceuticals Inc. and boceprevir from Merck and Co. Inc. in the U.S. It notes that both companies are competing to develop the first protease inhibitor for the treatment of hepatitis C virus (HCV) infection to...

  • Peginterferon-α-2a/ribavirin.  // Reactions Weekly;10/1/2011, Issue 1371, p30 

    The article describes the case of a 53-year-old man who developed bronchial cast expectoration while being treated with peginterferon-&alpha-2a and ribavirin for chronic hepatitis C.

  • Peginterferon-α-2b/ribavirin.  // Reactions Weekly;10/20/2012, Issue 1424, p40 

    The article describes the case of a 62-year-old man who developed branch retinal artery occlusion (BRAO) and central retinal vein occlusion (CRVO) during treatment with peginterferon-α-2b and ribavirin for chronic hepatitis C infection.

  • Filgrastim/peginterferon-α-2a/ribavirin.  // Reactions Weekly;1/29/2011, Issue 1336, p22 

    The article describes the case report of a 54-year-old female patient with chronic hepatitis C, and who developed severe recurrent neutropenia, thrombocytopenia and agranulocytosis during long-term therapy with SC peginterferon-α-2a combined with ribavirin.

  • Peginterferon/ribavirin.  // Reactions Weekly;11/13/2010, Issue 1327, p30 

    The article describes the case of depression and fatigue in two men while receiving treatment with peginterferon and ribavirin for chronic hepatitis C.

  • CORRECTIONS.  // JAMA: Journal of the American Medical Association;11/13/2013, Vol. 310 Issue 18, p1987 

    A correction to the article "Sofosbuvir and Ribavirin for Hepatitis C Genotype 1 in Patients With Unfavorable Treatment Characteristics: A Randomized Clinical Trial" in the Augst 28, 2013 issue is presented.

  • Interferon-α-2b/ribavirin.  // Reactions Weekly;1/8/2011, Issue 1333, p25 

    The article describes the case of a 30-year-old man who developed Vogt-Koyanagi-Harada (VKH) diseases during treatment with interferon-α-2b and ribavirin for a chronic hepatitis C virus infection.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics